Caris Life Sciences (CAI) vs Oscar Health (OSCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oscar Health (OSCR) has outperformed Caris Life Sciences (CAI) over the past year, gaining 51.8% versus a loss of 16.5%. Oscar Health is the larger company by market cap ($10.22 billion vs $7.77 billion), about 1.3 times the size, while Caris Life Sciences is growing revenue faster (+97.0% vs +27.5%). On valuation, Oscar Health trades at a lower forward P/E (15.3x vs 74.7x for Caris Life Sciences).
Oscar Health converts more of its revenue into profit, with a net margin of -3.8% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | OSCR |
|---|---|---|
| Share price | $27.50 | $33.10 |
| Market cap | $7.77B | $10.22B |
| 1-day change | +1.48% | +0.58% |
| YTD return | +1.93% | +130.34% |
| 1-year return | -16.54% | +51.83% |
| 5-year return | — | +108.83% |
| P/E ratio (TTM) | 16.27 | 25.66 |
| Forward P/E | 74.69 | 15.29 |
| EPS (TTM) | $1.69 | $1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $812.03M | $11.70B |
| Revenue growth (YoY) | +96.97% | +27.50% |
| Net income (latest FY) | $-68.09M | $-443.15M |
| Operating margin | 5.56% | -3.39% |
| Net margin | -8.38% | -3.79% |
| 52-week high | $33.65 | $34.48 |
| 52-week low | $14.19 | $10.69 |
| Distance from 52-week high | -18.28% | -4.00% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +5.75% | +6.95% |
| Average volume | 4.94M | 5.20M |
| Shares outstanding | 282.68M | 273.47M |
| Employees | 1,846 | 2,305 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSCR has outperformed CAI by 68.4 percentage points over the past year.
- Oscar Health trades at a higher earnings multiple (25.7x vs 16.3x trailing P/E).
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +27.50%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Oscar Health
OSCR stock →Oscar Health, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 2,305 employees
CAI vs OSCR FAQ
Which is bigger, Caris Life Sciences or Oscar Health?
Oscar Health (OSCR) is larger, with a market capitalization of $10.22B compared with $7.77B for Caris Life Sciences (CAI).
Which stock has performed better over the past year, CAI or OSCR?
OSCR returned +51.83% over the past 12 months, compared with -16.54% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or OSCR?
CAI has the lower trailing P/E at 16.3, versus 25.7 for OSCR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Caris Life Sciences and Oscar Health in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.